Ubs Asset Management Americas Inc Halozyme Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

  • $381 Billion
  • Q3 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 397,833 shares of HALO stock, worth $18.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
397,833
Previous 432,024 7.91%
Holding current value
$18.8 Million
Previous $22.6 Million 0.62%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$51.3 - $64.42 $1.75 Million - $2.2 Million
-34,191 Reduced 7.91%
397,833 $22.8 Million
Q2 2024

Aug 13, 2024
BUY
$37.81 - $52.4 $10.2 Million - $14.2 Million
271,070 Added 168.41%
432,024 $22.6 Million
Q1 2024

May 15, 2024
SELL
$33.68 - $41.95 $7,611 - $9,480
-226 Reduced 0.14%
160,954 $6.55 Million
Q4 2023

Feb 14, 2024
BUY
$33.32 - $42.1 $121,384 - $153,370
3,643 Added 2.31%
161,180 $5.96 Million
Q3 2023

Nov 13, 2023
SELL
$36.46 - $44.03 $6.46 Million - $7.8 Million
-177,071 Reduced 52.92%
157,537 $6.02 Million
Q1 2023

May 15, 2023
SELL
$32.86 - $55.7 $6.04 Million - $10.2 Million
-183,871 Reduced 35.46%
334,608 $12.8 Million
Q4 2022

Feb 14, 2023
SELL
$40.06 - $59.44 $58,968 - $87,495
-1,472 Reduced 0.28%
518,479 $29.5 Million
Q3 2022

Nov 14, 2022
BUY
$38.53 - $51.78 $13.2 Million - $17.8 Million
343,087 Added 193.98%
519,951 $20.6 Million
Q2 2022

Aug 12, 2022
BUY
$37.35 - $48.3 $351,052 - $453,971
9,399 Added 5.61%
176,864 $7.78 Million
Q1 2022

May 16, 2022
BUY
$31.97 - $41.06 $530,606 - $681,472
16,597 Added 11.0%
167,465 $6.68 Million
Q4 2021

Feb 14, 2022
BUY
$31.82 - $40.75 $99,596 - $127,547
3,130 Added 2.12%
150,868 $6.07 Million
Q3 2021

Nov 15, 2021
SELL
$38.47 - $46.42 $290,717 - $350,795
-7,557 Reduced 4.87%
147,738 $6.01 Million
Q2 2021

Aug 16, 2021
BUY
$38.84 - $51.31 $162,856 - $215,142
4,193 Added 2.77%
155,295 $7.05 Million
Q1 2021

May 14, 2021
SELL
$39.51 - $51.45 $121,493 - $158,208
-3,075 Reduced 1.99%
151,102 $6.3 Million
Q4 2020

Mar 01, 2021
BUY
$25.81 - $43.62 $334,936 - $566,056
12,977 Added 9.19%
154,177 $6.58 Million
Q3 2020

Nov 13, 2020
SELL
$25.74 - $29.63 $107,902 - $124,208
-4,192 Reduced 2.88%
141,200 $3.71 Million
Q2 2020

Aug 14, 2020
SELL
$16.25 - $26.81 $11.8 Million - $19.5 Million
-727,800 Reduced 83.35%
145,392 $3.9 Million
Q1 2020

May 15, 2020
SELL
$13.9 - $21.83 $2.57 Million - $4.04 Million
-185,137 Reduced 17.49%
873,192 $15.7 Million
Q4 2019

Feb 14, 2020
BUY
$14.93 - $19.53 $2.53 Million - $3.31 Million
169,391 Added 19.06%
1,058,329 $18.8 Million
Q3 2019

Nov 14, 2019
BUY
$15.2 - $17.69 $11.7 Million - $13.7 Million
772,005 Added 660.21%
888,938 $13.8 Million
Q2 2019

Aug 15, 2019
BUY
$14.75 - $17.26 $247,564 - $289,691
16,784 Added 16.76%
116,933 $0
Q1 2019

May 14, 2019
BUY
$13.94 - $17.58 $97,580 - $123,059
7,000 Added 7.51%
100,149 $0
Q4 2018

Feb 13, 2019
BUY
$13.33 - $18.66 $53,106 - $74,341
3,984 Added 4.47%
93,149 $1.36 Million
Q3 2018

Nov 14, 2018
SELL
$16.68 - $18.41 $12,326 - $13,604
-739 Reduced 0.82%
89,165 $0
Q2 2018

Aug 14, 2018
BUY
$16.87 - $20.3 $51,706 - $62,219
3,065 Added 3.53%
89,904 $0
Q1 2018

May 14, 2018
BUY
$17.06 - $21.2 $42,957 - $53,381
2,518 Added 2.99%
86,839 $0
Q4 2017

Feb 09, 2018
BUY
$16.75 - $20.8 $101,387 - $125,902
6,053 Added 7.73%
84,321 $0
Q3 2017

Nov 13, 2017
BUY
$11.76 - $17.4 $920,431 - $1.36 Million
78,268
78,268 $0

Others Institutions Holding HALO

# of Institutions
543
Shares Held
125M
Call Options Held
294K
Put Options Held
180K
View Full List

About HALOZYME THERAPEUTICS, INC.

HALO Quotes by TradingView
  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.57B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email